Panpan Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Panpan Ma has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Hao Kong
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
35 shared publications - Hong Jiang
West China Hospital of Sichuan University
35 shared publications - Lang Chen
Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China
35 shared publications - Xiangji Wu
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
35 shared publications - Yun-Hua Liu
Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
35 shared publications - Chengxuan Yu
Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
24 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s3 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
GO enrichment analysis of genes identified through CUT&Tag data
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s3 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
GO enrichment analysis of genes identified through CUT&Tag data
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S26 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Supplementary Fig. S1 shows representative images of human adjacent normal and PDAC tissues post-surgery, alongside representative images of Masson's trichrome staining for human adjacent normal and PDAC tissues. Supplementary Fig. S2 depicts quality control results of spatial transcriptomics, identifies cell types in human normal pancreas and PDAC tissues, and maps the spatial distribution of major cell types in sections of human adjacent normal and PDAC tissues. Supplementary Fig. S3 displays representative mIHC staining images of human adjacent normal and PDAC tissues. Supplementary Fig. S4 illustrates the mIHC staining and quantification of LYVE1+ macrophages in soft and stiff PDAC tumors. Supplementary Fig. S5 presents the mRNA expression levels of mechanosensitive ion channels and integrins in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S6 illustrates the gating strategy for bone marrow-derived monocytes and macrophages, along with representative monocyte gating in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S7 displays the quality control results of scRNA-seq data derived from human blood and PDAC samples. Supplementary Fig. S8 presents a spatiotemporal analysis of monocytes and macrophages in blood and PDAC tissues from human PDAC patients. Supplementary Fig. S9 illustrates the subcutaneous simulation of PDAC models by injecting stiff or soft hydrogels mixed with KPC cells. Supplementary Fig. S10 presents the protein expression levels of FAK in PYK2-deficient monocytes/macrophages. Supplementary Fig. S11 illustrates the influence of PYK2 on macrophage mechanotransduction in vivo. Supplementary Fig. S12 illustrates the polarization profiles of WT and Ptk2b KO BMDMs under stimulation with LPS, IL-4/IL-13, or conditioned medium. Supplementary Fig. S13 shows PYK2 deficient BMDMs exhibit impaired cell migration. Supplementary Fig. S14 illustrates the impact of PIEZO1 agonists or inhibitors on monocyte differentiation. Supplementary Fig. S15 shows the role of PYK2 as a transcriptional co-regulator in conjunction with AP-1 and/or SP-1. Supplementary Fig. S16 illustrates the effects of PYK2 deficiency in myeloid precursors on the TME and tumor growth in mouse PDAC models. Supplementary Fig. S17 displays the gating strategy and quantitative analysis of myeloid cells and lymphocytes in tissues from mouse PDAC models. Supplementary Fig. S18 presents the gating strategy and quantitative analysis of T cells within a co-culture system of T cells and monocytes/macrophages. Supplementary Fig. S19 illustrates the impact of myeloid-specific PYK2 deficiency on the TME and its enhancement of immunotherapy efficacy in mouse PDAC models. Supplementary Fig. S20 presents the quality control metrics for scRNA-seq data of PDAC tumors from WT + Iso, WT+αPD-1, Ptk2b KO + Iso and Ptk2b KO+αPD-1 groups. Supplementary Fig. S21 depicts the transcriptional profiles of monocytes, macrophages, and fibroblasts across single and combination treatment groups. Supplementary Fig. S22 shows the impact of myeloid-specific Ptk2b deficiency on fibrosis in mouse PDAC tissues. Supplementary Fig. S23 showed the distinct functional profiles of fibroblasts across experimental groups. Supplementary Fig. S24 illustrates the analysis of CD8+ T cells using flow cytometry and mIHC across single and combination treatment groups. Supplementary Fig. S25 shows the palpation-based tumor size measurements for orthotopic PDAC tumors in mice. Supplementary Fig. S26 shows the full Western blot images alongside their corresponding quantitative analyses.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S26 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Supplementary Fig. S1 shows representative images of human adjacent normal and PDAC tissues post-surgery, alongside representative images of Masson's trichrome staining for human adjacent normal and PDAC tissues. Supplementary Fig. S2 depicts quality control results of spatial transcriptomics, identifies cell types in human normal pancreas and PDAC tissues, and maps the spatial distribution of major cell types in sections of human adjacent normal and PDAC tissues. Supplementary Fig. S3 displays representative mIHC staining images of human adjacent normal and PDAC tissues. Supplementary Fig. S4 illustrates the mIHC staining and quantification of LYVE1+ macrophages in soft and stiff PDAC tumors. Supplementary Fig. S5 presents the mRNA expression levels of mechanosensitive ion channels and integrins in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S6 illustrates the gating strategy for bone marrow-derived monocytes and macrophages, along with representative monocyte gating in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S7 displays the quality control results of scRNA-seq data derived from human blood and PDAC samples. Supplementary Fig. S8 presents a spatiotemporal analysis of monocytes and macrophages in blood and PDAC tissues from human PDAC patients. Supplementary Fig. S9 illustrates the subcutaneous simulation of PDAC models by injecting stiff or soft hydrogels mixed with KPC cells. Supplementary Fig. S10 presents the protein expression levels of FAK in PYK2-deficient monocytes/macrophages. Supplementary Fig. S11 illustrates the influence of PYK2 on macrophage mechanotransduction in vivo. Supplementary Fig. S12 illustrates the polarization profiles of WT and Ptk2b KO BMDMs under stimulation with LPS, IL-4/IL-13, or conditioned medium. Supplementary Fig. S13 shows PYK2 deficient BMDMs exhibit impaired cell migration. Supplementary Fig. S14 illustrates the impact of PIEZO1 agonists or inhibitors on monocyte differentiation. Supplementary Fig. S15 shows the role of PYK2 as a transcriptional co-regulator in conjunction with AP-1 and/or SP-1. Supplementary Fig. S16 illustrates the effects of PYK2 deficiency in myeloid precursors on the TME and tumor growth in mouse PDAC models. Supplementary Fig. S17 displays the gating strategy and quantitative analysis of myeloid cells and lymphocytes in tissues from mouse PDAC models. Supplementary Fig. S18 presents the gating strategy and quantitative analysis of T cells within a co-culture system of T cells and monocytes/macrophages. Supplementary Fig. S19 illustrates the impact of myeloid-specific PYK2 deficiency on the TME and its enhancement of immunotherapy efficacy in mouse PDAC models. Supplementary Fig. S20 presents the quality control metrics for scRNA-seq data of PDAC tumors from WT + Iso, WT+αPD-1, Ptk2b KO + Iso and Ptk2b KO+αPD-1 groups. Supplementary Fig. S21 depicts the transcriptional profiles of monocytes, macrophages, and fibroblasts across single and combination treatment groups. Supplementary Fig. S22 shows the impact of myeloid-specific Ptk2b deficiency on fibrosis in mouse PDAC tissues. Supplementary Fig. S23 showed the distinct functional profiles of fibroblasts across experimental groups. Supplementary Fig. S24 illustrates the analysis of CD8+ T cells using flow cytometry and mIHC across single and combination treatment groups. Supplementary Fig. S25 shows the palpation-based tumor size measurements for orthotopic PDAC tumors in mice. Supplementary Fig. S26 shows the full Western blot images alongside their corresponding quantitative analyses.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s4 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The GO enrichment analysis results of monocyte/macrophage cell subtype markers
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s4 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The GO enrichment analysis results of monocyte/macrophage cell subtype markers
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s1 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The patient information of ST samples
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s1 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The patient information of ST samples
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s2 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Gene markers, DEGs and GSEA analysis
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s2 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Gene markers, DEGs and GSEA analysis
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Data from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibrotic, stiff tumor microenvironment in which tumor-associated macrophages (TAM) drive extracellular matrix remodeling, progression, and immune evasion. The contribution of mechanical cues to monocyte differentiation into TAMs remains largely unexplored. In this study, we show that mechanical force is required for monocyte-to-macrophage differentiation. PYK2, as an immunomechanical checkpoint, de facto governs this differentiation process. We demonstrated that PYK2 senses mechanical signals via PIEZO1 and integrins, triggering F-actin polymerization and translocating to the nucleus to regulate mechanotransduction and differentiation genes (e.g., ACTR3, RELA). Targeted deletion of Ptk2b, which encodes PYK2 impairs the differentiation and polarization of monocyte-derived macrophages, reshapes the PDAC microenvironment, and enhances the efficacy of anti–PD-1 immunotherapy. These findings underscore the critical role of mechanical cues in monocyte differentiation and suggest that targeting PYK2 is a promising strategy to modulate TAM function and improve immunotherapy outcomes in patients with PDAC.Significance:This study identifies PYK2 as an immunomechanical checkpoint that drives monocyte-to-macrophage differentiation in PDAC via PIEZO1/integrin-mediated mechanical cues. Targeted deletion of Ptk2b (PYK2) reshapes the PDAC microenvironment and enhances the efficacy of anti–PD-1 immunotherapy, suggesting PYK2 as a promising therapeutic target to overcome immunotherapy resistance.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibrotic, stiff tumor microenvironment in which tumor-associated macrophages (TAM) drive extracellular matrix remodeling, progression, and immune evasion. The contribution of mechanical cues to monocyte differentiation into TAMs remains largely unexplored. In this study, we show that mechanical force is required for monocyte-to-macrophage differentiation. PYK2, as an immunomechanical checkpoint, de facto governs this differentiation process. We demonstrated that PYK2 senses mechanical signals via PIEZO1 and integrins, triggering F-actin polymerization and translocating to the nucleus to regulate mechanotransduction and differentiation genes (e.g., ACTR3, RELA). Targeted deletion of Ptk2b, which encodes PYK2 impairs the differentiation and polarization of monocyte-derived macrophages, reshapes the PDAC microenvironment, and enhances the efficacy of anti–PD-1 immunotherapy. These findings underscore the critical role of mechanical cues in monocyte differentiation and suggest that targeting PYK2 is a promising strategy to modulate TAM function and improve immunotherapy outcomes in patients with PDAC.Significance:This study identifies PYK2 as an immunomechanical checkpoint that drives monocyte-to-macrophage differentiation in PDAC via PIEZO1/integrin-mediated mechanical cues. Targeted deletion of Ptk2b (PYK2) reshapes the PDAC microenvironment and enhances the efficacy of anti–PD-1 immunotherapy, suggesting PYK2 as a promising therapeutic target to overcome immunotherapy resistance.